ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as … Read more
Market Cap & Net Worth: ABIVAX Société Anonyme (AAVXF)
ABIVAX Société Anonyme (PINK:AAVXF) has a market capitalization of $546.39 Million ($546.39 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #11687 globally and #5168 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ABIVAX Société Anonyme's stock price $6.91 by its total outstanding shares 79072628 (79.07 Million).
ABIVAX Société Anonyme Market Cap History: 2016 to 2025
ABIVAX Société Anonyme's market capitalization history from 2016 to 2025. Data shows change from $606.26 Million to $546.39 Million (-2.85% CAGR).
ABIVAX Société Anonyme Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ABIVAX Société Anonyme's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
80.96x
ABIVAX Société Anonyme's market cap is 80.96 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $606.26 Million | $151.00K | -$14.31 Million | 4014.95x | N/A |
| 2017 | $778.87 Million | $356.00K | -$11.22 Million | 2187.82x | N/A |
| 2018 | $880.87 Million | $815.00K | -$15.82 Million | 1080.82x | N/A |
| 2019 | $1.97 Billion | $-7.00K | -$30.63 Million | -281272.63x | N/A |
| 2020 | $3.24 Billion | $14.00K | -$37.55 Million | 231569.84x | N/A |
| 2021 | $2.53 Billion | $37.00K | -$41.36 Million | 68387.14x | N/A |
| 2022 | $457.83 Million | $4.58 Million | -$69.85 Million | 99.90x | N/A |
| 2023 | $805.75 Million | $4.62 Million | -$147.74 Million | 174.37x | N/A |
| 2024 | $873.75 Million | $10.79 Million | -$176.24 Million | 80.96x | N/A |
Competitor Companies of AAVXF by Market Capitalization
Companies near ABIVAX Société Anonyme in the global market cap rankings as of March 18, 2026.
Key companies related to ABIVAX Société Anonyme by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ABIVAX Société Anonyme Historical Marketcap From 2016 to 2025
Between 2016 and today, ABIVAX Société Anonyme's market cap moved from $606.26 Million to $ 546.39 Million, with a yearly change of -2.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $546.39 Million | -37.47% |
| 2024 | $873.75 Million | +8.44% |
| 2023 | $805.75 Million | +75.99% |
| 2022 | $457.83 Million | -81.91% |
| 2021 | $2.53 Billion | -21.95% |
| 2020 | $3.24 Billion | +64.66% |
| 2019 | $1.97 Billion | +123.52% |
| 2018 | $880.87 Million | +13.10% |
| 2017 | $778.87 Million | +28.47% |
| 2016 | $606.26 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ABIVAX Société Anonyme was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $546.39 Million USD |
| MoneyControl | $546.39 Million USD |
| MarketWatch | $546.39 Million USD |
| marketcap.company | $546.39 Million USD |
| Reuters | $546.39 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.